Intuitive Surgical (ISRG) Delivers +19% Revenue Growth in Q2 2026
Key Takeaways
- Q2 2026 revenue reached $2.89 billion, up 19% year over year and above consensus estimates.
- Non-GAAP diluted EPS of $2.80 beat analyst expectations by approximately $0.32 to $0.39.
- Worldwide da Vinci and Ion procedures grew about 16% year over year.
- 468 da Vinci systems placed, including 246 da Vinci 5 systems, expanding the installed base to 11,710.
- Full-year 2026 guidance reaffirmed with da Vinci procedure growth expected at 13.5% to 15.5%.
- GAAP net income rose to $818 million, or $2.29 per diluted share.
Earnings Context and Why It Matters
Intuitive Surgical’s quarterly results provide key insights into demand for its robotic-assisted surgical systems and related instruments. Strong procedure volume growth signals continued adoption of minimally invasive techniques across hospitals worldwide. The report also highlights system placements, leasing trends, and margin performance, which influence investor views on the company’s long-term growth trajectory in the medical device sector.
Reported Results
Intuitive Surgical reported second-quarter 2026 revenue of $2.89 billion, a 19% increase from $2.44 billion in the same quarter of 2025. Instruments and accessories revenue rose 18% to $1.73 billion, while systems revenue increased to $685 million. Non-GAAP net income attributable to the company reached $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, a year earlier. GAAP net income was $818 million, or $2.29 per diluted share. Both revenue and non-GAAP EPS exceeded consensus estimates. Worldwide procedures grew approximately 16%, with da Vinci procedures up about 15% and Ion procedures up 36%. The company placed 468 da Vinci systems and 55 Ion systems during the quarter. I also checked this using Tickeron’s AI Screener to see how ISRG compares to others in the industry.
Market Reaction and Investor Sentiment
Shares of ISRG typically move on earnings beats driven by procedure growth and system placements. The strong Q2 results, including revenue and earnings outperformance, reinforced positive sentiment heading into the report. Investors focused on the company’s ability to sustain momentum amid broader healthcare spending trends and adoption of robotic surgery.
Forward Outlook and Key Factors to Monitor
Intuitive Surgical reaffirmed its 2026 full-year outlook, expecting worldwide da Vinci procedure growth of 13.5% to 15.5%. Non-GAAP gross profit margin is projected in the 68.0% to 69.0% range, incorporating an estimated 1.0% impact from tariffs. Non-GAAP operating expense growth is anticipated between 11% and 13%.
Investors will watch procedure volume trends, system placement rates, and the mix between capital sales and leasing arrangements. The expanding installed base of da Vinci and Ion systems supports recurring revenue from instruments and accessories. Tariff developments and their effect on margins remain a key variable through year-end. Upcoming catalysts include updates on digital solutions and new system adoption rates. From what I see, these factors will be important to track closely in the coming quarters.
How Tickeron’s AI Screener Fits Into My Research
As part of my regular analysis process, I turn to Tickeron’s AI Screener to filter stocks and ETFs by technical patterns, fundamentals, and performance metrics. This tool helps me quickly identify how a company like ISRG stacks up against peers and spot broader sector trends that might not be obvious from the earnings release alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsContributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ISRG in upward trend: price rose above 50-day moving average on September 14, 2026
ISRG moved above its 50-day moving average on September 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 50 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on September 14, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in 28 of 44 cases over the following month. The odds of a continued upward trend are 64%.
The 10-day moving average for ISRG crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +3.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 213 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 14 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 37%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 62 cases where ISRG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ISRG entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ISRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.065) is normal, around the industry mean (5.011). P/E Ratio (47.568) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.074).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther
Advertisement